AJIC: American Journal of Infection Control
Volume 37, Issue 5 , Pages 387-397, June 2009

Surgical site infection: Incidence and impact on hospital utilization and treatment costs

  • Gregory de Lissovoy, PhD, MPH

      Affiliations

    • United BioSource Corporation, Bethesda MD
    • Corresponding Author InformationAddress correspondence to Greg de Lissovoy, PhD, Senior Research Scientist, United BioSource Corporation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814.
  • ,
  • Kathy Fraeman, SM

      Affiliations

    • United BioSource Corporation, Bethesda MD
  • ,
  • Valerie Hutchins, BS

      Affiliations

    • United BioSource Corporation, Bethesda MD
  • ,
  • Denise Murphy, RN, MPH, CIC

      Affiliations

    • Barnes-Jewish Hospital, St. Louis, MO
  • ,
  • David Song, MD

      Affiliations

    • University of Chicago Hospitals, Chicago, IL
  • ,
  • Brian B. Vaughn, MPA, MBA

      Affiliations

    • ETHICON Inc., Somerville, NJ

published online 24 April 2009.

Background

Surgical site infections (SSIs) are serious operative complications that occur in approximately 2% of surgical procedures and account for some 20% of health care-associated infections.

Methods

SSI was identified based on the presence of ICD-9-CM diagnosis code 998.59 in hospital discharge records for 7 categories of surgical procedures: neurological; cardiovascular; colorectal; skin, subcutaneous tissue, and breast; gastrointestinal; orthopedic; and obstetric and gynecologic. Source of data was the 2005 Healthcare Cost and Utilization Project National Inpatient Sample (HCUP NIS). Primary study outcomes were rate of SSI by surgical category and impact of SSI on length of stay and cost. Results were projected to the national level.

Results

Among 723,490 surgical hospitalizations in the sample, 6891 cases of SSI were identified (1%). On average, SSI extended length of stay by 9.7 days while increasing cost by $20,842 per admission. From the national perspective, these cases of SSI were associated with an additional 406,730 hospital-days and hospital costs exceeding $900 million. An additional 91,613 readmissions for treatment of SSI accounted for a further 521,933 days of care at a cost of nearly $700 million.

Conclusion

SSI is associated with a significant economic burden in terms of extended length of stay and increased costs of treatment. Our analysis documented nearly 1 million additional inpatient-days and $1.6 billion in excess costs.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 14.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial support for this study was provided by ETHICON, Inc.

PII: S0196-6553(09)00073-X

doi:10.1016/j.ajic.2008.12.010

AJIC: American Journal of Infection Control
Volume 37, Issue 5 , Pages 387-397, June 2009